Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.

Cancer science - 1 Mar 2024

Sun Mengyao, Gu Yun, Fang Hanji, Shao Fei, Lin Chao, Zhang Heng, Li He, He Hongyong, Li Ruochen, Wang Jieti, Liu Hao, Xu Jiejie

Abstract excerpt

Chromatin remodelers are commonly altered in human cancer. The mutation of AT-rich interactive domain 1A (ARID1A) in gastric cancer (GC), a component of the SWI/SNF chromatin remodeling complex, was proven associated with treatment response in our previous study. However, ARID1A loss of function was caused not only by mutations but also copy number deletions. The clinicopathologic, genomic, and immunophenotypic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to MicroRNA in disease regulation

Share to Mutation

Share to Nuclear Proteins

Share to Stomach Neoplasms

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 38148578
DOI: 10.1111/cas.16057
PMCID: PMC10920992

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.PMID 38148578Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic InterpretationSemantic proximity Read ↗

Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.Semantic proximity Read ↗

Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair DeficiencySemantic proximity Read ↗

The effects of ARID1A mutation in gastric cancer and its significance for treatmentSemantic proximity Read ↗

Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studiesSemantic proximity Read ↗

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.Semantic proximity Read ↗

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.Semantic proximity Read ↗

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studySemantic proximity Read ↗

Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.Semantic proximity Read ↗

ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal CancerSemantic proximity Read ↗

Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.